ITGAX and neoplasm: In MDSCs at the tumor site, phenotype changes were less significant than in splenic MDSCs; however, we found the increase in expressions of maturation markers, F4/80 and CD11c on the surface of MDSCs induced by oxaliplatin treatment (Figure 5D).